Oncology Corporate Profile
Biovest International develops personalized immunotherapies for life threatening cancers of the blood system. Biovest is the holder of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute for the commercialization of BiovaxID, a personalized biologic therapeutic cancer vaccine for the treatment of non-Hodgkin's lymphoma. This therapy, referred to as BiovaxID, is currently in a phase 3 pivotal trial at 24 major medical institutions in the US.
This company does not have any pipeline products
1/13/2014 11:55 am
(Financial Post) Jan 13, 2014 - Biovest International, Inc. today reported that the European Medicines Agency (EMA) accepted the Company’s Marketing Authorization Application (MAA) for BiovaxID™ (submitted to EMA as “Dasiprotimut-T Biovest”), a personalized cancer vaccine for the treatment of non-Hodgkin’s follicular lymphoma.
8/23/2013 02:35 pm
(Florida Biotechnology News) Aug 22, 2013 - Biovest International, Inc., a pioneer in the development of personalized cancer vaccines, has successfully emerged from Chapter 11 reorganization, formally completing its restructuring and recapitalization strategy with its Plan of Reorganization becoming effective on July 9, 2013.
7/18/2013 10:54 am
(CenterWatch) July 17, 2013 - Biovest International, a developer of personalized cancer vaccines, has emerged from Chapter 11 reorganization, formally completing its restructuring and recapitalization strategy with its reorganization plan.
10/12/2012 10:04 am
(Dallas Morning News/Investigates blog) Oct 11, 2012 - As my colleague Sue Goetinck Ambrose reported earlier, the director of Texas’ cancer-fighting agency recently asked some scientific reviewers to reconsider poor scores they gave to an applicant’s request for state dollars.
8/14/2012 11:41 am
(Miami Herald) Aug 14, 2012 - Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that it conducted a formal clinical guidance meeting with the U.S. FDA to determine the most expeditious U.S. registration pathway for BiovaxID™, its personalized cancer vaccine for the consolidation treatment of follicular non-Hodgkin’s lymphoma.
7/12/2012 12:09 pm
(Marketwatch) July 12, 2012 - The European Medicines Agency (EMA) has provided formal notification that Biovest is eligible to submit its planned Marketing Authorization Application (MAA) for BiovaxID under the EMA's centralized procedure as an orphan medicinal product for the treatment of follicular non-Hodgkin's lymphoma.
6/20/2012 12:07 pm
(Marketwatch) June 20, 2012 - Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. today announced that formal notification was submitted to the European Medicines Agency (EMA) informing of Biovest's intent to file a Marketing Authorization Application (MAA) seeking approval in the European Union (EU) for BiovaxID(R), its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.
4/16/2012 09:01 am
(Fox News) Apr 15, 2012 - Oncologists may now have a better way to classify – and ultimately treat – breast cancer. Researchers out of the Mayo Clinic in Jacksonville, Fla., have uncovered a new class of molecular mutations in breast cancer tissue – a discovery that could lead to a better understanding of how to provide individualistic treatment for the disease.
11/23/2011 10:01 am
(AGA) Nov 21, 2011 - Certain patients with inflammatory bowel disease (IBD) may have an increased risk of skin cancer, which is intensified by the use of immunosuppressant medications.
10/27/2011 12:32 pm
(TheStreet) Oct 27, 2011 - Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID® for the treatment of Waldenstrom’s macroglobulinemia, a rare subtype of B-cell non-Hodgkin’s lymphoma.
10/6/2011 12:51 pm
(Miami Herald) Oct 6, 2011 - Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that it has started the process to conduct clinical pre-filing discussions with various regulatory agencies including Health Canada, the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA).
5/19/2011 12:04 pm
(Amgen) May 18, 2011 - Amgen today announced that data from studies involving nine Amgen products will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3 - 7, 2011 in Chicago.
4/25/2011 12:04 pm
(HealthImaging.com) Apr 22, 2011 - Senator Dianne Feinstein (D-Calif.), and co-sponsors Senator John Isakson (R-Ga.) and Senator John Kerry (D-Mass.), have introduced the Lung Cancer Mortality Reduction Act of 2011 (S. 752).
4/6/2011 01:00 pm
(Fox Chase CC) Apr 5, 2011 - A nutrient found in carrots and sweet potatoes may prove key to fighting breast cancer at early stages, according to a new study by researchers at Fox Chase Cancer Center.
3/25/2011 12:02 pm
(ASCO Connection Blog) Mar 25, 2011 - As an organization of clinical oncologists, ASCO has a special and lasting interest in the fate of the nation's Cooperative Oncology Groups.